drugset / Trial / NCT06922825
Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients
Phase 0
Withdrawn
Eben Rosenthal
Vanderbilt University Medical Center · collabVanderbilt-Ingram Cancer Center · collab
NaSingle-groupOpen-labelBasic science
Summary
This pilot study aims to compare PET/CT imaging using 68Ga-FAPI-46 to imaging results from standard MRI or CT with contrast in patients with solid tumors undergoing biologic therapy. A total of 50 participants will receive an intravenous injection of 68Ga-FAPI-46 and undergo a PET/CT scan shortly after received the study drug. Imaging will occur before starting standard antibody-based therapy. Participants will then proceed with their treatment, and the study team will monitor them through chart reviews for up to 36 months to evaluate treatment response and any correlation with tumor uptake observed on PET/CT scans.
Timeline
- Start
- 2027-01
- Primary completion
- 2032-04
- Completion
- 2032-09
Outcome
Outcome not reported
Stopped (Enrollment): “No patients enrolled onto study. Administratively withdrawn.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-FAPI-46 | Diagnostic / imaging agent | — | Intravenous |